Lung Adenocarcinoma Treatment Market Growth & Trends
The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).
The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.
Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.
In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.
Lung Adenocarcinoma Treatment Market Report Highlights
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook